Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and ...

AnaptysBio Inc. (NASDAQ:ANAB) announced that its investigational drug, rosnilimab, demonstrated a best-in-disease profile in ...

AnaptysBio Inc.’s shares rose to a six-month high on Tuesday following the announcement of successful Phase 2b results from ...

Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs Max response rates have not yet been observed; strict continuation criteria at three months in this ...

a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT. During the webcast, members of Anaptys management ...

Highlights of the poster presentation entitled, “S-4321, a novel dual-cell bidirectional PD-1:FcγRIIb selective agonist antibody for the treatment of autoimmune disease,” include ...

A phase 2 basket trial of tarlatamab in patients with advanced DLL3-expressing tumors: University of California Lung Cancer Consortium UCCC-01/UCLA L-10. This is an ASCO Meeting Abstract from the 2025 ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has hit the goals of a phase 2 rheumatoid arthritis (RA) trial. The phase 2b ...

The absence of this motif makes mouse PD-1 significantly weaker than human PD-1. “Although many proteins in mice and humans have similar sequences, receptors in the immune system often show greater ...

Format – Fireside chat and one-on-one investor meetings Date and Time – Wednesday, June 11, 2025, at 8:40am ET / 5:40am PT Live webcasts of the data release, as well as the presentation ...

WATERTOWN, Mass., November 18, 2024--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of new data for S-4321, its next ...